Suppliers / Laboratorium Ofichem

Laboratorium Ofichem

Germany Updated 9 July 2026

Laboratorium Ofichem is a finished-dose manufacturer based in Germany. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with EMA, NMPA (CN) and MINSA (CR). Its GMP standing is certified by ZLG (DE), US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 12 October 2023 as VAI.

2
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
21
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
0 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 12 October 2023 VAI US FDA
  • 18 September 2019 NAI US FDA
  • 17 December 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Dusseldorf, Germany Not on file
Duesseldorf, Germany Not on file
Netherlands, Netherlands 1000286391

What they file, and where

Molecule Regulators Docs
Dimethyl Fumarate US FDA 1
Histamine Phosphate US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 19 1
NMPA (CN) 1 None
MINSA (CR) 1 None
ZLG (DE) None 4
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Laboratorium Ofichem comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 October 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates